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Knowledge of the distinctive cellular and genetic traits of a cancer aids in diagnosis, prognosis, and poten-
tially treatment. In this issue of Cancer Cell, Kotecha et al. (2008) demonstrate using a sophisticated flow cy-
tometry approach that signal transduction responses to exogenous stimulation can inform diagnosis and
pathobiology of myeloproliferative neoplasms.The disorderly order of tumorigenesis
makes it a wonder that cancer diagnostics
and prognostics have been utilized to date
with any efficacy. Cancers can be identi-
fied by tissue, cellular, and molecular char-
acteristics, and much work has been com-
mitted to correlating these characteristics
with diagnostic and prognostic utility, with
several notable successes. However, re-
cent technological advances promise to
improve our current strategies for diagno-
sis and treatment of cancer, as exempli-
fied herein by Kotecha et al. (2008).
Juvenile myelomonocytic leukemia
(JMML) is an invasiveand clinically aggres-
sive myeloproliferative disorder (MPD)
or neoplasm that arises from primitive
stem or myeloid progenitor cells (Lapidot
et al., 1996; Emanuel, 2008). Accurate
diagnosis is essential given the aggressive
nature of JMML and limited therapeutic
options (see Emanuel, 2008 for diagnostic
criteria). Although current clinical criteria
are adequate in most cases, they repre-
sent indirect manifestations of the under-
lying pathogenetic basis of the disease.
The molecular underpinnings of JMML
are exceptionally well characterized and
can largely be attributed to mutational
activation of the RAS/MAP kinase
(MAPK) pathway. Mutations in the RAS
family members KRAS or NRAS, the non-
receptor tyrosine phosphatase SHP2
(PTPN11), or the RAS-GAP NF1 are ob-
served in 65%–85% of JMML patients
(Schubbert et al., 2007; Emanuel, 2008).
Furthermore, these mutations are largely
mutually exclusive between patients with
the same clinical phenotype, indicating at
least partially redundant function. En-
gagement of RAS signaling results in acti-
vation of multiple effectors including the
canonical MAPK pathway converging on
ERK activation, the PI3K/AKT pathway,the RAL pathway, and activation of
PKC and RAC (Schubbert et al., 2007).
The balance of these signaling outputs
regulates numerous cellular processes in-
cluding survival and proliferation, and
thus, dysregulated pathway activation
might reasonably result in the observed
JMML phenotype. Indeed, evidence for
causality of these mutations comes from
data obtained using mouse models that
recapitulate many of the phenotypic attri-
butes of JMML (Schubbert et al., 2007;
Emanuel, 2008). Although the identifica-
tion of mutations in RAS, PTPN11, or
NF1 is potentially useful in diagnostic as-
sessment of JMML, exclusion of their mu-
tations does not eliminate a diagnosis of
JMML.
Elevated RAS/MAPK pathway activa-
tion presumably explains the hypersensi-
tivity to granulocyte-macrophage col-
ony-stimulating factor (GM-CSF) that
was described prior to genetic insights
into disease. Myelomonocytic progeni-
tors from the bone marrow (BM) or periph-
eral blood (PB) of JMML patients display
enhanced colony growth in vitro in the
presence of low doses of GM-CSF that
do not support the growth of healthy BM
or PB progenitors (Emanuel et al., 1991).
GM-CSF normally stimulates hematopoi-
etic development, as well as inflammatory
responses, acting through its cognate
GM-CSF receptor, which is comprised of
a ligand-binding a subunit and a common
bc signal-transducing subunit (Guthridge
et al., 1998). JMML mutations apparently
confer hypersensitivity to stimulation with
GM-CSF and may sensitize cells to GM-
CSF antagonists (Iversen et al., 1997; Ber-
nard et al., 2002; Kim et al., 2007).
Aberrant signaling networks are
thought to be critical drivers of cancer
cell growth, proliferation, and survival,Cancer Cell 1a notion that has led to development of ef-
fective therapies that target these signal-
ing networks. These observations provide
an impetus for a detailed understanding of
these pathways in cancer to inform novel
therapeutic strategies, as well as our un-
derstanding of the dependence of cancer
cells on these pathways. Technological
advances reported by Garry Nolan and
others have informed this effort through
use of multiparametric flow cytometry at
the single-cell level to study signal trans-
duction from primary patient material. In
a seminal paper (Irish et al., 2004), the No-
lan laboratory measured both extracellu-
lar and intracellular parameters from
primary acute myelogenous leukemia
(AML) samples stimulated with a number
of hematopoietic agonists. By measuring
changes in phosphoprotein levels as sur-
rogates for activation of their respective
pathways, the authors could cluster AML
samples according to several signaling
signatures. Importantly, these signaling
signatures correlated well with various
clinical parameters, including response
to chemotherapy, receptor tyrosine ki-
nase mutations (namely FLT3), and cyto-
genetic status (Irish et al., 2004). Of further
interest, individual signaling profiles for
each AML patient could be constructed
based on flow cytometry data. This study
paved the way for using signaling signa-
tures not only for drug target discovery
purposes but also for diagnostic and pos-
sible prognostic use.
Extending these concepts to JMML,
Kotecha et al. (2008) sought to identify
aberrant signaling responses to GM-
CSF in primary JMML cell samples, using
the schema shown in Figure 1. The
obvious suspects would have been
members of the RAS/MAPK pathway.
Quite surprisingly, phospho-ERK (p-ERK4, October 7, 2008 ª2008 Elsevier Inc. 279
Cancer Cell
Previews[Thr202/Tyr204]) and p-S6
(Ser235/236, a readout of both
RAS/MAPK and mTOR activa-
tion) responses to GM-CSF
were quite heterogeneous in
JMML samples and had minimal
utility in identifying a unique sig-
naling signature in JMML sam-
ples compared to controls. How-
ever, the authors did identify
a subpopulation of monocytic
cells in the PB and BM of JMML
patients with the surface immu-
nophenotype CD33+CD14+CD34
CD38lo that displayed elevated
levels of p-STAT5 (Tyr694) when
stimulated with low doses of
GM-CSF. This p-STAT5 re-
sponse to low levels of GM-CSF
was not observed in other types
of childhood MPDs or in healthy
individuals. The response was
readily detectable at diagnosis,
disappeared when the patient
was treated and in remission,
but recrudesced in patients at
time of relapse or transformation
to AML. The aberrant signaling
signature was also shared with
patients having related leuke-
mias, including chronic myelo-
monocytic leukemia (CML) and
the M4/M5 subtype of AML. Im-
portantly, this signature was not
merely a surrogate assay for
standard progenitor colony
growth. Patients with Noonan
syndrome, who harbor relatively
weak germline PTPN11 gain-of-function
mutations and develop transient MPDs,
often did not display the hyperactive
p-STAT5 signature yet had progenitors
that were hypersensitive to GM-CSF
in vitro. This hyperactive p-STAT5 re-
sponse was abolished in JMML patient
cells through pretreatment with a JAK2
inhibitor, but not with a MEK inhibitor, im-
plying that hyperactive JAK2 activity un-
derlies this p-STAT5 response in JMML
monocytic cells.
This elegant report exemplifies the
value of studying signaling networks in pri-
mary patient material. In the context of
JMML, this approach has identified novel
signaling elements at play in JMML in the
form of the JAK-STAT pathway, suggests
the possibility of therapeutic targeting
of the pathway, and provides potential
for the development of new and more ac-
curate diagnostics. It should be noted in
this context that these investigators are
arguably the best in this arena and that
technical requirements for single-cell
flow cytometry from primary patient mate-
rial—especially for labile signal transduc-
tion intermediates—may be challenging
in conventional clinical laboratories. The
report also raises a number of interesting
questions for further study. For example,
it would be of considerable interest to as-
sess the role of JAK-STAT pathway inhibi-
tion in biological readouts and to under-
stand how gain-of-function mutations in
RAS or SHP2 (PTPN11) result in JAK-
STAT pathway activation. Another inter-
esting point raised by this report is that
the immunophenotype described does
not match the CD34+CD38 phenotype
previously reported to contain JMML-
initiating cell activity in a xenotransplant
mouse model (Lapidot et al.,
1996). Does the GM-CSF-hyper-
sensitive population identified by
Kotecha et al. (2008) contain can-
cer stem cell activity or contrib-
ute to disease pathogenesis,
and how do the two immunophe-
notypes correspond biologically
and from a signal transduction
perspective? In addition, it would
be of value to assess the validity
of this approach in the various
murine models of disease—
given the rarity of JMML and the
technical challenges in working
with primary human samples, it
would be useful to determine
whether some of these questions
could be addressed in model
systems. However, it is clear
that technological advances,
such as those described here,
are continuing to have a dramatic
impact on our understanding of
pathophysiology, diagnosis, and
potentially treatment of cancer.
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Figure 1. Identifying Unique Signaling Profiles in Primary
Patient Samples
Shown is a flow chart essentially outlining the strategy used by Kote-
cha et al. (2008) to identify signaling abnormalities in primary juvenile
myelomonocytic leukemia (JMML) samples. Cells from primary patient
samples are stimulated with one or more agonists ex vivo and then un-
dergo fixation and permeabilization. Samples can then be stored or
stained for surface and/or intracellular (IC) antigens. The samples are
then analyzed by flow cytometry, and signaling responses can be
grouped (as shown in the hypothetical heat map representation) ac-
cording to the strength of response to a given perturbation (in this ex-
ample, increased concentration of agonist). Signaling profiles (SPs)
can be deduced and potentially correlated with clinical parameters,
such as type of disease, response to therapy, mutational status, etc.
(as in Irish et al., 2004; Kotecha et al., 2008).
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